Crisaborole Pfizer-Homepage | Rwanda | Healthier World Accord

Crisaborole Pfizer

Home

About

Mechanism of Action

Efficacy

Phase III Study Primary Endpoints

Success in ISGA: Clear or almost clear

Study Design

Phase III Study Secondary Endpoints

ISGA clear or almost clear

Time to ISGA success

Phase III Study: Other Endpoints

Pruritus

Quality of life assessments

Infant Study: Exploratory efficacy Endpoints

ISGA clear or almost clear

%BSA, EASI & POEM

Safety

Important Safety Information

Phase III Study Adverse Reactions*

Pivotal trial & 48-week extension study Adverse Reactions

Open-Label Safety Extension Study*

Open-Label Safety Extension Study Rescue Therapy Endpoint

Study design

Infant Safety Study**

Adverse Reactions

Study design and Demographics

Dosing

Medical Information

Visit the Pfizer Medical Information Africa Website for Healthcare Professionals

Submit a medical question to Pfizer

To report an adverse event, please contact [email protected]

Crisaborole Pfizer: A steroid-free option

For the treatment of mild-to-moderate atopic dermatitis in patients 3 months and older

Infant Safety Study in patients 3 to <24 months of age

Learn more about a 28-day, single-arm, open-label safety study in 3 to <24 month old patients⁴

Learn more

Efficacy

Crisaborole Pfizer has proven efficacy across all pivotal trial primary and secondary endpoints in patients aged 2 years and up^1,2

Learn more

Safety Data

Learn more about the safety data of Crisaborole Pfizer from the 4-week pivotal trials and open-label safety extension study^1,3

View safety data

Dosing

For topical use only. Not for ophthalmic, oral or intravaginal use

Understand more

References

Crisaborole Pfizer (crisaborole) Full Prescribing Information. April 2020.

Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e4.

Eichenfield LF, Tom WL, Berger TJ, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1)116-132.

Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020. 21:275-284.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

To report an adverse event, please contact [email protected]
Click here to Submit a Medical Question.
Terms of Use
Cookies & Privacy Policy
Contact: KENYA OFFICE: Pfizer Laboratories (Pty) Ltd Vienna Court, First Floor West Wing, State House Crescent, State House Road, Nairobi Kenya, PO Box 18244-00500.
Tel: +254(0)5134110.
Pfizer.com

This site is intended only for Rwanda health care professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

Disclaimer: The product is not yet licensed by the Board of Health of Rwanda (Rwanda FDA). The product has however obtained prior Board of Health approval for supply to Accord program channels in Rwanda.

You are now leaving Accord Portal to access Pfizer Medical Information Portal

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.